HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ('Moleculin” or the 'Company”), today announced that an abstract featuring pooled cardiac safety data for its lead drug candidate Annamycin (also known as 'L-Annamycin” or 'naxtarubicin”), has been accepted for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2, 2026, in Chicago, Illinois. Access the abstract here.